Recursion Signs a Worldwide License Agreement with Takeda to Develop TAK-733 for Hereditary Cancer Syndrome

 Recursion Signs a Worldwide License Agreement with Takeda to Develop TAK-733 for Hereditary Cancer Syndrome

Recursion Signs a Worldwide License Agreement with Takeda to Develop TAK-733 for Hereditary Cancer Syndrome

Shots:

  • Recursion to get exclusive WW rights to develop and commercialize TAK-733 for the treatment of a hereditary cancer syndrome and related areas of oncology
  • Recursion will utilize its automated drug discovery platform to discover the potential of TAK-733 by testing 200+ potential molecules from Takeda’s library against cancers carrying mutations
  • TAK-733 is identified as a potential treatment for a hereditary tumor syndrome using Recursion’s approach for creating cellular models of diseases with inactive genes

Click here ­to­ read full press release/ article | Ref: Business wire | Image: Recursion

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post